Unicycive Therapeutics to Join Healthcare Innovation Forum
Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a pioneering biotechnology firm known for its commitment to developing treatments for kidney ailments, is set to engage in a significant fireside chat during a prestigious healthcare conference. The event will take place during the Guggenheim 2nd Annual Healthcare Innovation Conference, where Dr. Shalabh Gupta, the Company’s Chief Executive Officer, will be present to share vital insights into the company’s ongoing efforts and advancements.
Spotlight on Conference Participation
Scheduled for November 10, the discussion will commence at 3:30 p.m. ET. This initiative is part of Unicycive’s ongoing strategy to promote its groundbreaking research and foster connections with potential investors and healthcare stakeholders. The engagement at this conference puts Unicycive in a prime position to highlight its innovative therapies, focusing particularly on chronic kidney disease.
What’s on the Agenda?
During the fireside chat, discussions will revolve around Unicycive's lead investigational product, oxylanthanum carbonate. This novel phosphate-binding agent is currently under review for treating hyperphosphatemia in patients with chronic kidney disease who require dialysis. Attendees can expect valuable insights into the product's status and future prospects as it navigates regulatory reviews.
Innovative Treatments for Kidney Health
In addition to oxylanthanum carbonate, Unicycive is advancing another investigational treatment known as UNI-494. This therapy focuses on conditions connected to acute kidney injuries. Notably, UNI-494 has received orphan drug designation from the FDA for preventing Delayed Graft Function (DGF) in kidney transplant recipients and has completed safety trials in healthy volunteers.
Company Overview
Unicycive Therapeutics is dedicated to creating novel treatments targeting kidney diseases. The company prioritizes patient needs in its research and development endeavors. Its innovative pipelines reflect an understanding of the complexities involved in managing kidney conditions, particularly for vulnerable populations like those on dialysis or those undergoing transplantation procedures.
Investor Insights and Future Prospects
Participants in the conference will have opportunities to engage in 1x1 meetings with the management team to discuss investment opportunities and understand the strategic direction of Unicycive. This engagement underscores the company’s commitment to transparency and investor relations.
How to Access the Webcast
For those unable to attend in person, the conference will feature live and archived webcasts, which can be accessed through the Unicycive website’s Investors section. This ensures that stakeholders and interested parties stay informed about the company’s progress and developments.
Media and Investor Communication
Unicycive values open communication with the media and investors alike. With designated contacts for inquiries, the company ensures that its stakeholders receive timely updates and information regarding its initiatives.
Frequently Asked Questions
What is Unicycive Therapeutics known for?
Unicycive Therapeutics is recognized for developing innovative therapies aimed at treating kidney diseases, especially through its lead treatments.
When is the fireside chat scheduled?
The fireside chat will occur on November 10 at 3:30 p.m. ET during the Guggenheim 2nd Annual Healthcare Innovation Conference.
What treatments are being highlighted?
The discussions will primarily focus on oxylanthanum carbonate and UNI-494, both aimed at improving kidney health and patient outcomes.
How can investors interact with Unicycive during the conference?
Investors will have the opportunity to book 1x1 meetings with the management team to explore investment options and learn more about the company’s initiatives.
Where can I find more information about Unicycive?
For additional details, visit Unicycive’s official website or their Investors section to access webcasts and other resources.
